AU2007213804B2 - Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products - Google Patents

Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products Download PDF

Info

Publication number
AU2007213804B2
AU2007213804B2 AU2007213804A AU2007213804A AU2007213804B2 AU 2007213804 B2 AU2007213804 B2 AU 2007213804B2 AU 2007213804 A AU2007213804 A AU 2007213804A AU 2007213804 A AU2007213804 A AU 2007213804A AU 2007213804 B2 AU2007213804 B2 AU 2007213804B2
Authority
AU
Australia
Prior art keywords
antibody
monoclonal antibody
tumor
met monoclonal
antimet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007213804A
Other languages
English (en)
Other versions
AU2007213804A1 (en
AU2007213804A8 (en
Inventor
Paolo Maria Comoglio
Silvia Giordano
Elisa Vigna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertical Bio AG
Original Assignee
Vertical Bio AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertical Bio AG filed Critical Vertical Bio AG
Publication of AU2007213804A1 publication Critical patent/AU2007213804A1/en
Publication of AU2007213804A8 publication Critical patent/AU2007213804A8/en
Application granted granted Critical
Publication of AU2007213804B2 publication Critical patent/AU2007213804B2/en
Assigned to VERTICAL BIO AG reassignment VERTICAL BIO AG Request for Assignment Assignors: METHERESIS TRANSLATIONAL RESEARCH S.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007213804A 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products Active AU2007213804B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06101345.4 2006-02-06
EP06101345 2006-02-06
PCT/EP2007/051066 WO2007090807A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Publications (3)

Publication Number Publication Date
AU2007213804A1 AU2007213804A1 (en) 2007-08-16
AU2007213804A8 AU2007213804A8 (en) 2008-08-28
AU2007213804B2 true AU2007213804B2 (en) 2012-12-13

Family

ID=36616994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007213804A Active AU2007213804B2 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Country Status (21)

Country Link
US (2) US8388958B2 (OSRAM)
EP (2) EP2192188A1 (OSRAM)
JP (1) JP5306828B2 (OSRAM)
KR (1) KR101429297B1 (OSRAM)
CN (1) CN101379192B (OSRAM)
AT (1) ATE514715T1 (OSRAM)
AU (1) AU2007213804B2 (OSRAM)
BR (1) BRPI0707480A8 (OSRAM)
CA (1) CA2638889C (OSRAM)
CY (1) CY1111884T1 (OSRAM)
DK (1) DK1981981T3 (OSRAM)
EA (1) EA015580B1 (OSRAM)
ES (1) ES2368864T3 (OSRAM)
IL (1) IL192879A (OSRAM)
MX (1) MX2008009833A (OSRAM)
PL (1) PL1981981T3 (OSRAM)
PT (1) PT1981981E (OSRAM)
SG (2) SG169383A1 (OSRAM)
SI (1) SI1981981T1 (OSRAM)
WO (1) WO2007090807A1 (OSRAM)
ZA (1) ZA200806559B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) * 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) * 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
WO2011125458A1 (ja) * 2010-04-02 2011-10-13 富士レビオ株式会社 抗癌剤の効果の診断用マーカー
AU2011261161A1 (en) * 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
KR20140019284A (ko) * 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
EP3165538A1 (en) 2010-11-03 2017-05-10 Argen-X Nv Anti c-met antibodies
EP2500036B1 (en) * 2011-03-18 2014-05-07 Metheresis Translational Research SA MET inhibitors for enhancing radiotherapy efficacy
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
US20130129718A1 (en) 2011-11-21 2013-05-23 Genentech, Inc. Purification of anti-c-met antibodies
EP2785741A1 (en) 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US10377827B2 (en) * 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and compositions
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
WO2016149265A1 (en) * 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
CN116731177A (zh) 2016-09-29 2023-09-12 田边三菱制药株式会社 cMET单克隆结合剂、其药物缀合物及其用途
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
KR20200138288A (ko) * 2018-03-28 2020-12-09 미쓰비시 타나베 파마 코퍼레이션 cMET 모노클로날 결합제의 약물 접합체, 및 그의 용도
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
WO2024246356A1 (en) 2023-06-01 2024-12-05 Pierre Fabre Medicament Silenced antibody-based anti-met constructs for the treatment of tumors and metastasis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CORSO, S. et al, Trends in Molecular Medicine, 2005, Vol. 11, No. 6, pages 284-292 *

Also Published As

Publication number Publication date
KR20090013745A (ko) 2009-02-05
ZA200806559B (en) 2012-12-27
US8729043B2 (en) 2014-05-20
IL192879A0 (en) 2009-02-11
EA015580B1 (ru) 2011-10-31
SI1981981T1 (sl) 2012-01-31
PL1981981T3 (pl) 2011-11-30
CA2638889C (en) 2015-06-02
MX2008009833A (es) 2008-10-23
IL192879A (en) 2014-02-27
CY1111884T1 (el) 2015-11-04
DK1981981T3 (da) 2011-09-26
KR101429297B1 (ko) 2014-08-12
EP1981981A1 (en) 2008-10-22
ES2368864T3 (es) 2011-11-23
US20120134996A1 (en) 2012-05-31
AU2007213804A1 (en) 2007-08-16
CA2638889A1 (en) 2007-08-16
CN101379192B (zh) 2013-07-31
SG169382A1 (en) 2011-03-30
US8388958B2 (en) 2013-03-05
JP2009526010A (ja) 2009-07-16
WO2007090807A1 (en) 2007-08-16
BRPI0707480A8 (pt) 2022-11-08
US20090285807A1 (en) 2009-11-19
EP2192188A1 (en) 2010-06-02
CN101379192A (zh) 2009-03-04
BRPI0707480A2 (pt) 2011-05-03
EA200870234A1 (ru) 2009-02-27
PT1981981E (pt) 2011-10-04
JP5306828B2 (ja) 2013-10-02
SG169383A1 (en) 2011-03-30
ATE514715T1 (de) 2011-07-15
EP1981981B1 (en) 2011-06-29
AU2007213804A8 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
AU2007213804B2 (en) Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
Zatovicova et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain
US7531304B2 (en) Method for screening FGFR-4 agonists
JP5016487B2 (ja) 新規な抗ｉｇｆ−ｉｒ抗体及びその使用
EP2819695B1 (en) ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US20110212091A1 (en) Materials and methods for inhibiting cancer cell invasion
AU2003205716A1 (en) FGFR agonists
US20090123462A1 (en) Fgfr agonists
EP2507265B1 (en) Antibody specific for heparanase splice variant T5 and its use.
US20060024314A1 (en) Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 22, NO 32, PAGE(S) 3806 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME METHERESIS TRANSLATION RESEARCH S.A., APPLICATION NO. 2007213804, UNDER INID (71), CORRECT THE NAME TO METHERESIS TRANSLATIONAL RESEARCH S.A.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: VERTICAL BIO AG

Free format text: FORMER OWNER(S): METHERESIS TRANSLATIONAL RESEARCH S.A.